Several brokerages have updated their recommendations and price targets on shares of AmerisourceBergen (NYSE: ABC) in the last few weeks:

  • 1/8/2019 – AmerisourceBergen was downgraded by analysts at TheStreet from a “b-” rating to a “c+” rating.
  • 1/7/2019 – AmerisourceBergen was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 1/7/2019 – AmerisourceBergen was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “AmerisourceBergen continues to gain from, businesses like World Courier and Xcenda which have been raking in huge profits since quite some time. The company’s specialty distribution business also continues to contribute significantly to its topline. Additionally, AmerisourceBergen’s Global Commercialization Services and Animal Health unit saw a strong fourth quarter. A positive guidance for 2019 buoys optimism. On the flip side, dull performances in the company’s PharMEDium and Lash units have been a headwind in the last couple of quarters. Contraction in gross and operating margin in the last reported quarter raises concern. The company faces other headwinds like conversion of branded drugs and lower price generics. Cutthroat competition in the MedTech space adds to the woes. AmerisourceBergen has underperformed the industry in a year’s time.”
  • 1/6/2019 – AmerisourceBergen had its “hold” rating reaffirmed by analysts at Barclays PLC. They now have a $84.00 price target on the stock.
  • 12/31/2018 – AmerisourceBergen was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “AmerisourceBergen has underperformed the industry in a year’s time. Dull performances in the company’s PharMEDium and Lash units have been a headwind in the last couple of quarters. Contraction in gross and operating margin in the last reported quarter raises concern. The company faces other headwinds like conversion of branded drugs and lower price generics. Cutthroat competition in the MedTech space adds to the woes. On the brighter side, AmerisourceBergen continues to gain from, businesses like World Courier and Xcenda which have been raking in huge profits since quite some time. The company’s specialty distribution business also continues to contribute significantly to its topline. Additionally, AmerisourceBergen’s Global Commercialization Services and Animal Health unit saw a strong fourth quarter. A positive guidance for 2019 buoys optimism.”
  • 12/19/2018 – AmerisourceBergen was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “AmerisourceBergen has underperformed the industry in a year’s time. Dull performances in the company’s PharMEDium and Lash units have been a headwind in the last couple of quarters. Contraction in gross and operating margin in the last reported quarter raises concern. The company faces other headwinds like conversion of branded drugs and lower price generics. Cutthroat competition in the MedTech space adds to the woes. On the brighter side, AmerisourceBergen continues to gain from, businesses like World Courier and Xcenda which have been raking in huge profits since quite some time. The company’s specialty distribution business also continues to contribute significantly to its topline. Additionally, AmerisourceBergen’s Global Commercialization Services and Animal Health unit saw a strong fourth quarter. A positive guidance for 2019 buoys optimism.”
  • 12/13/2018 – AmerisourceBergen was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “AmerisourceBergen has underperformed the industry in a year’s time. Dull performances in the company’s PharMEDium and Lash units have been a headwind in the last couple of quarters. Contraction in gross and operating margin in the last reported quarter raises concern. The company faces other headwinds like conversion of branded drugs and lower price generics. Cutthroat competition in the MedTech space adds to the woes. On the brighter side, AmerisourceBergen continues to gain from, businesses like World Courier and Xcenda which have been raking in huge profits since quite some time. The company’s specialty distribution business also continues to contribute significantly to its topline. Additionally, AmerisourceBergen’s Global Commercialization Services and Animal Health unit saw a strong fourth quarter. A positive guidance for 2019 buoys optimism.”
  • 12/4/2018 – AmerisourceBergen was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “AmerisourceBergen’s dull performances in the PharMEDium and Lash unit have been a headwind in the last couple of quarters. Contraction in gross and operating margin in the last reported quarter raises concern. The company faces other headwinds like conversion of branded drugs and lower price generics. Cutthroat competition in the MedTech space adds to the woes. On the brighter side, the company continues to gain from, businesses like World Courier and Xcenda which have been raking in huge profits since quite some time. The company’s specialty distribution business also continues to contribute significantly to its topline. Additionally, AmerisourceBergen’s Global Commercialization Services and Animal Health unit saw a strong fourth quarter. A positive guidance for 2019 buoys optimism. AmerisourceBergen has outperformed the industry in a year’s time. “
  • 12/3/2018 – AmerisourceBergen had its price target raised by analysts at Morgan Stanley from $88.00 to $91.00. They now have an “equal weight” rating on the stock.
  • 11/30/2018 – AmerisourceBergen had its price target lowered by analysts at Royal Bank of Canada from $90.00 to $87.00. They now have a “hold” rating on the stock.
  • 11/28/2018 – AmerisourceBergen was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “AmerisourceBergen’s dull performance in the PharMEDium and Lash unit have been a headwind in the last couple of quarters. Contraction in gross and operating margin in the last reported quarter raises concern. The company faces other headwinds like conversion of branded drugs and lower price generics. Cutthroat competition in the MedTech space adds to the woes. On the positive side, businesses like World Courier and Xcenda have been raking in huge profits since quite some time. AmerisourceBergen also continues to gain from its specialty distribution business. Additionally, AmerisourceBergen’s Global Commercialization Services and Animal Health unit saw a strong fourth quarter. A positive guidance for 2019 buoys optimism. The stock has outperformed the industry in a year’s time.”
  • 11/22/2018 – AmerisourceBergen was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “AmerisourceBergen exited the fiscal fourth quarter on a tepid note. While earnings edged past the consensus mark, revenues lagged the same. On the brighter side, businesses like World Courier and Xcenda, exceeded expectations in the quarter. AmerisourceBergen also continues to gain from its specialty distribution business. Additionally, AmerisourceBergen’s Global Commercialization Services and Animal Health unit saw a strong fourth quarter. A positive guidance for 2019 buoys optimism. The stock has outperformed the industry in a year’s time. However, lower PharMEDium and Lash unit sales partially marred segmental operating income in the quarter. Contraction in gross and operating margin raises concern. Earnings in the first quarter of fiscal 2019 are expected to remain down. The company faces headwinds like conversion of branded drugs and lower price generics. Cutthroat competition in the MedTech space adds to the woes.”
  • 11/16/2018 – AmerisourceBergen was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “AmerisourceBergen exited the fiscal fourth quarter on a tepid note. While earnings edged past the consensus mark, revenues lagged the same. However, businesses like World Courier and Xcenda, exceeded expectations in the quarter. AmerisourceBergen also continues to gain from its specialty distribution business. Additionally, AmerisourceBergen’s Global Commercialization Services and Animal Health unit saw a strong fourth quarter. A positive guidance for 2019 buoys optimism. AmerisourceBergen has outperformed the industry in a year’s time. On the flip side, lower PharMEDium and Lash unit sales partially marred segmental operating income in the quarter. Contraction in gross and operating margin raises concern. Earnings in the first quarter of fiscal 2019 are expected to remain down. The company faces headwinds like conversion of branded drugs and lower price generics. Cutthroat competition in the MedTech space adds to the woes.”

NYSE ABC opened at $76.56 on Monday. The firm has a market capitalization of $16.17 billion, a PE ratio of 11.80, a PEG ratio of 1.22 and a beta of 1.08. AmerisourceBergen Corp. has a 52 week low of $69.36 and a 52 week high of $106.27. The company has a quick ratio of 0.50, a current ratio of 0.93 and a debt-to-equity ratio of 1.48.

AmerisourceBergen (NYSE:ABC) last released its earnings results on Tuesday, November 6th. The company reported $1.45 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.44 by $0.01. AmerisourceBergen had a return on equity of 45.54% and a net margin of 0.99%. The company had revenue of $43.30 billion during the quarter, compared to analysts’ expectations of $43.27 billion. During the same period last year, the firm earned $1.33 EPS. The business’s revenue for the quarter was up 10.7% on a year-over-year basis. As a group, equities research analysts expect that AmerisourceBergen Corp. will post 6.81 EPS for the current year.

In related news, EVP Kathy H. Gaddes sold 2,652 shares of AmerisourceBergen stock in a transaction on Monday, October 22nd. The stock was sold at an average price of $92.96, for a total transaction of $246,529.92. Following the completion of the sale, the executive vice president now directly owns 3,891 shares of the company’s stock, valued at $361,707.36. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Steven H. Collis sold 21,350 shares of AmerisourceBergen stock in a transaction on Wednesday, January 2nd. The stock was sold at an average price of $73.96, for a total value of $1,579,046.00. Following the sale, the chief executive officer now directly owns 155,929 shares of the company’s stock, valued at $11,532,508.84. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 133,127 shares of company stock valued at $11,528,306. 27.30% of the stock is owned by insiders.

Several institutional investors have recently made changes to their positions in ABC. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in AmerisourceBergen by 140.9% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,142 shares of the company’s stock worth $105,000 after acquiring an additional 668 shares in the last quarter. Financial Gravity Wealth Inc. lifted its holdings in AmerisourceBergen by 93.2% during the third quarter. Financial Gravity Wealth Inc. now owns 1,254 shares of the company’s stock worth $108,000 after acquiring an additional 605 shares in the last quarter. Truvestments Capital LLC bought a new position in AmerisourceBergen during the third quarter worth about $120,000. Livingston Group Asset Management CO operating as Southport Capital Management bought a new position in AmerisourceBergen during the third quarter worth about $130,000. Finally, Centaurus Financial Inc. bought a new position in AmerisourceBergen during the second quarter worth about $129,000. 65.87% of the stock is owned by institutional investors and hedge funds.

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers.

Recommended Story: Trading Penny Stocks

Receive News & Ratings for AmerisourceBergen Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen Corp and related companies with MarketBeat.com's FREE daily email newsletter.